SRx Health Solutions Inc美股招股说明书(2026-02-26版)

This prospectus supplement updates and supplements the information contained in the prospectus dated December 15, 2025 (as maybe supplemented or amended from time to time, the “Prospectus”), which forms part of our registration statement on Form S-1 (FileNo. 333-291262), as amended, with the information contained in our Current Report on Form 8-K which was filed with the Securitiesand Exchange Commission on February 20, 2026 (the “Current Report”). Accordingly, we have attached the Current Report to thisprospectus supplement. The Prospectus and this prospectus supplement relate to the resale, from time to time, which may be offered by Keystone CapitalPartners, LLC (“Keystone”, “Keystone Capital Partners” or the “Selling Stockholder”), or their pledgees, donees, transferees, or othersuccessors in interest, of up to 2,506,893,959 shares of common stock, par value $0.0001 per share (the “Common Stock”), of SRxHealth Solutions, Inc., a Delaware corporation (“we,” “our,” the “Company”). The shares of Common Stock being offered by theSelling Stockholder are outstanding or issuable pursuant to the Common Share Purchase Agreement dated July 7, 2025 by and amongthe Company and the Selling Stockholder, as amended on October 28, 2025 (the “ELOC Purchase Agreement”). See “The KeystoneCapital Transaction” for a description of the Purchase Agreement. We may elect, in our sole discretion, to issue and sell such2,506,893,959 shares of Common Stock (the “Keystone Purchase Shares”) to Keystone, from time to time from and after the KeystoneCommencement Date (as defined below) under the ELOC Purchase Agreement. Please refer to “Selling Stockholder” beginning onpage 70. Such registration does not mean that Keystone will actually offer or sell any of these shares of Common Stock. We will notreceive any proceeds from the sales of the above shares of Common Stock by the Selling Stockholder; however, we will receiveproceeds under the Purchase Agreement if we sell shares of Common Stock to the Selling Stockholder. You should read this prospectus supplement in conjunction with the Prospectus. This prospectus supplement is qualified by referenceto the Prospectus except to the extent that the information in this prospectus supplement supersedes the information contained in theProspectus. This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, theProspectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely onthe information in this prospectus supplement. Terms used in this prospectus supplement but not defined herein shall have themeanings given to such terms in the Prospectus. You should read this prospectus and any prospectus supplement or amendment carefully before you invest in our securities. Our Common Stock is listed on the NYSE American under the symbol “SRXH”. On February 25, 2026, the closing price of ourCommon Stock was $0.1360 per share. We are a “smaller reporting company” under applicable federal securities laws and will be subject to reduced public companyreporting requirements for so long as we remain a smaller reporting company. Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussionof the risks of investing in our securities in “Risk Factors”beginning on page 8 of this prospectus and any other risk factorscontained in any applicable prospectus supplement and in the documents incorporated by reference herein and therein. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesecurities to be issued under this prospectus or determined if this prospectus is truthful or complete. Any representation to thecontrary is a criminal offense. The date of this prospectus supplement is February 26, 2026. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 18, 2026 SRx Health Solutions, Inc.(Exact name of Registrant as Specified in its Charter) 801 US Highway 1North Palm Beach, Florida 33408(Address of Principal Executive Offices) (Zip Code) (Registrant’s Telephone Number, Including Area Code):(212) 896-1254 N/A(Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrantunder any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exc